First Therapeutic Approval for Eosinophilic Esophagitis
Eosinophilic esophagitis (EE) is a chronic, immune-mediated or antigen-mediated esophageal disease. Treatment for patients with EE can be challenging with no previously approved medications. Current management strategies follow the four D’s paradigm of drugs, dietary elimination, dilation, and disea...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Gastroenterology Insights |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2036-7422/13/3/24 |
| _version_ | 1797488135656964096 |
|---|---|
| author | Rami A. Al-Horani Raquel Chiles |
| author_facet | Rami A. Al-Horani Raquel Chiles |
| author_sort | Rami A. Al-Horani |
| collection | DOAJ |
| description | Eosinophilic esophagitis (EE) is a chronic, immune-mediated or antigen-mediated esophageal disease. Treatment for patients with EE can be challenging with no previously approved medications. Current management strategies follow the four D’s paradigm of drugs, dietary elimination, dilation, and disease anxiety and hypervigilance therapy. On 20 May 2022, dupilumab was approved by FDA for EE. A dose of 300 mg dupilumab weekly significantly improved signs and symptoms of EE compared to placebo in a phase 3 trial. The approval of dupilumab will fulfill an unmet need for the increasing number of patients with EE. |
| first_indexed | 2024-03-09T23:58:41Z |
| format | Article |
| id | doaj.art-b61cd89a98ba43a98ee98f6e97ede89f |
| institution | Directory Open Access Journal |
| issn | 2036-7414 2036-7422 |
| language | English |
| last_indexed | 2024-03-09T23:58:41Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Gastroenterology Insights |
| spelling | doaj.art-b61cd89a98ba43a98ee98f6e97ede89f2023-11-23T16:21:11ZengMDPI AGGastroenterology Insights2036-74142036-74222022-07-0113323824410.3390/gastroent13030024First Therapeutic Approval for Eosinophilic EsophagitisRami A. Al-Horani0Raquel Chiles1Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USADivision of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USAEosinophilic esophagitis (EE) is a chronic, immune-mediated or antigen-mediated esophageal disease. Treatment for patients with EE can be challenging with no previously approved medications. Current management strategies follow the four D’s paradigm of drugs, dietary elimination, dilation, and disease anxiety and hypervigilance therapy. On 20 May 2022, dupilumab was approved by FDA for EE. A dose of 300 mg dupilumab weekly significantly improved signs and symptoms of EE compared to placebo in a phase 3 trial. The approval of dupilumab will fulfill an unmet need for the increasing number of patients with EE.https://www.mdpi.com/2036-7422/13/3/24esophagitisinflammation dupilumabmonoclonal antibodies |
| spellingShingle | Rami A. Al-Horani Raquel Chiles First Therapeutic Approval for Eosinophilic Esophagitis Gastroenterology Insights esophagitis inflammation dupilumab monoclonal antibodies |
| title | First Therapeutic Approval for Eosinophilic Esophagitis |
| title_full | First Therapeutic Approval for Eosinophilic Esophagitis |
| title_fullStr | First Therapeutic Approval for Eosinophilic Esophagitis |
| title_full_unstemmed | First Therapeutic Approval for Eosinophilic Esophagitis |
| title_short | First Therapeutic Approval for Eosinophilic Esophagitis |
| title_sort | first therapeutic approval for eosinophilic esophagitis |
| topic | esophagitis inflammation dupilumab monoclonal antibodies |
| url | https://www.mdpi.com/2036-7422/13/3/24 |
| work_keys_str_mv | AT ramiaalhorani firsttherapeuticapprovalforeosinophilicesophagitis AT raquelchiles firsttherapeuticapprovalforeosinophilicesophagitis |